Combined Effects of Alternate Nostril Breathing and Aerobic Interval Training on Blood Pressure and Heart Rate Products in Patients With Hypertension
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Experimental Group, interventional group A.
- Who it may be relevant to
- Registry conditions: Hypertension (HTN). Basic parameters: 25 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Pakistan
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Hypertension (HTN) is the foremost preventable risk factor for cardiovascular disease (CVD) and all-cause mortality, contributing to over 7 million deaths annually within the nearly 17 million attributed to CVD. Effective management through lifestyle modifications, including aerobic exercises specifically interval training presents a promising avenue for blood pressure regulation by promoting vasodilation and regulating the autonomic nervous system. Likewise, alternate nostril breathing has demonstrated efficacy in lowering blood pressure by optimizing oxygenation and improving endothelial function but their combined effect on BP measures is yet to be determined. Hence this study aims to determine the combined effects of aerobic interval training with and without alternate nostril breathing on blood pressure, rate pressure product and quality of life in patients with hypertension.
Interventions
- Other Experimental Group
The interventional group will perform aerobic training (stationary cycling) 3 days a week for 5 weeks, starting with 40-60% heart rate reserve (HRR) for 20-30 minutes, with thein the first week and increasing to 40-85% HRR, maintaining a target heart rate of 40-60% HRR at the lower end and 75-85% HRR at the upper end, following a 1:4 work-to-rest ratio for 30-40 minutes in subsequent weeks, with the warm up of 5 mins before the session and a cool down of 5-7 mins after every seasion. Exercise he - Other interventional group A
In interventional group 'A' participants will perform aerobic training for 3 days a week for 30-40 minutes a day for 5 consecutive weeks. Exercise heart rate will be calculated using the Karvonen formula. For the first base line week the aerobic session begins with a 5-minute warm-up. The primary cardiovascular component involves using a cycle ergometer (stationary cycling) at an intensity of 40-60% heart rate reserve (HRR) for 20-30 minutes. Finally, the workout will concludes with a cool-down
Primary outcome measures
- heart rate [Time frame: 05 weeks]
- blood pressure [Time frame: 05 weeks]
- Rate pressure product [Time frame: 05 weeks]
Eligibility criteria
Inclusion criteria
- Adults aged 25- 50 years -males and females
- Patients diagnosed with stage 1 hypertension 130 - 139 / 80 - 89 mmHg and stage 2 hypertension, BP level ≥140/90 mmHg. according to AHA/ACC 2017 Guidelines-Individuals who are able to understand and follow the instructions for exercise
Exclusion criteria
- Diagnosed with any current infections
- subjects with diagnosed musculoskeletal or neurological conditions which hinder participation in physical activity program
- Active Smokers
- Those with any contraindication to exercise testing or training.
- Pregnant females
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Pakistan · 1 center
- Foundation University College of Physical Therapy, Islamabad, 44000 — Rawalpindi
Identifiers
NCT: NCT07177989 · FUI/CTR/2025/92